Vancouver-based Chinese biotechnology firm Virogin Biotech has pocketed $62 million in a Series C round co-led by Chinese alternative management firm CDH Investments and CMG-SDIC Fund, a joint fund of state-owned SDIC Fund Management and China Merchants Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
